Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting of the American Society of Retina Specialists (ASRS) held July 17-20, in Stockholm, Sweden.
Dr. Anand’s presentation highlighted the interim results of the Skyline clinical trial, which is exploring a potential new subretinal gene therapy treatment for a specific type of retinitis pigmentosa. The study seeks to evaluate the safety and efficacy of two different doses of subretinal AGTC-501 gene therapy in patients with X-linked retinitis pigmentosa resulting from a mutation in the RPGR ORF15 gene. The most common inherited retinal disorder, retinitis pigmentosa changes how the retina responds to light, making it hard to see. It causes some photoreceptor cells to gradually fade and die, losing the ability to transmit visual messages to the brain.
Dr. Anand shared the 12-month Skyline study data, which demonstrated that both doses of AGTC-501 were generally safe and well-tolerated, with no clinically significant safety events related to the subretinal gene therapy. Additionally, data showed robust improvements in visual function with evidence of efficacy in study eyes of the high dose group when compared to study eyes in the low dose group.
“These favorable safety and efficacy results strongly support continued development of AGTC-501,” said Dr. Anand.
At ASRS 2024, Dr. Anand also earned a Senior Honor Award in recognition of his time and contributions to the scientific programs of the organization’s annual meetings. Sub-specializing in medical retina, vitreoretinal surgery and ocular oncology, he has served Texas Retina for 30 years and cares for patients in the Dallas Main, Dallas North, Denton and Plano offices.
Texas Retina’s Robert C. Wang, MD, and Ashkan M. Abbey, MD, also presented at the ASRS 2024 Annual Meeting.
About the American Society of Retina Specialists (ASRS)
ASRS is the largest organization of retinal specialists in the world, representing over 3,000 physicians in all 50 US states, the District of Columbia, Puerto Rico, and 63 countries. The Society serves as a national advocate and primary source of clinical and scientific information and education for its members.